Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 2Completed 2Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Melanoma 114Carcinoma, Non-Small-Cell Lung 34Neoplasms 26Neoplasm Metastasis 19Prostatic Neoplasms 18Uveal Melanoma 16Carcinoma, Renal Cell 16Lung Neoplasms 14Pancreatic Neoplasms 13Diabetes Mellitus, Insulin-Dependent, 12 12Small Cell Lung Carcinoma 11Colorectal Neoplasms 10Carcinoma, Hepatocellular 9Uterine Cervical Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Sarcoma 7Carcinoma, Transitional Cell 7Brain Neoplasms 7Stomach Neoplasms 6Mesothelioma 6Kidney Neoplasms 6Head and Neck Neoplasms 6Advanced Cancer 6Urinary Bladder Neoplasms 5Recurrence 5Ovarian Neoplasms 5Lymphoma, Non-Hodgkin 5Lymphoma 5Leukemia, Myeloid, Acute 5

Interventions

Cyclophosphamide 32Tacrolimus 29fludarabine 27Mycophenolic Acid 23fludarabine phosphate 22Busulfan 19Whole-Body Irradiation 18Melphalan 16Methotrexate 15Antilymphocyte Serum 14Rituximab 12Bortezomib 11Stem Cell Transplantation 10Cyclosporine 10thymoglobulin 9Sirolimus 9Granulocyte Colony-Stimulating Factor 9Peripheral Blood Stem Cell Transplantation 8Thiotepa 7Interviews as Topic 7Filgrastim 7Dexamethasone 7Clofarabine 7Blood Specimen Collection 6Alemtuzumab 6merphos 5Voriconazole 5Standard of Care 5Nivolumab 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hematologic Neoplasms × Ipilimumab × Clear all
NCT01919619 2024-12-03

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 2 Completed
41 enrolled 11 charts
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hematologic Neoplasms

NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

National Cancer Institute (NCI)

Phase 1 Completed
71 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡